|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0034656,
umls-concept:C0036525,
umls-concept:C0069717,
umls-concept:C0205210,
umls-concept:C0241315,
umls-concept:C0282460,
umls-concept:C0671970,
umls-concept:C0995188,
umls-concept:C1257890,
umls-concept:C1516225,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1708063,
umls-concept:C1956962
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-6-26
|
|
pubmed:abstractText |
To determine the activity and tolerability of adding cetuximab to the oxaliplatin and capecitabine (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:BornetCC,
pubmed-author:CasparCC,
pubmed-author:DietrichDD,
pubmed-author:HelblingDD,
pubmed-author:HerzNN,
pubmed-author:KappelerAA,
pubmed-author:KoeberleDD,
pubmed-author:LanzDD,
pubmed-author:MingroneWW,
pubmed-author:PestalozziBB,
pubmed-author:RauchDD,
pubmed-author:RothAA,
pubmed-author:RuhstallerTT,
pubmed-author:SalettiPP,
pubmed-author:Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland,
pubmed-author:TrojanAA,
pubmed-author:Von MoosRR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1288-92
|
|
pubmed:meshHeading |
pubmed-meshheading:18349029-Aged,
pubmed-meshheading:18349029-Aged, 80 and over,
pubmed-meshheading:18349029-Antibodies, Monoclonal,
pubmed-meshheading:18349029-Antineoplastic Agents,
pubmed-meshheading:18349029-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18349029-Colorectal Neoplasms,
pubmed-meshheading:18349029-Drug Administration Schedule,
pubmed-meshheading:18349029-Exanthema,
pubmed-meshheading:18349029-Female,
pubmed-meshheading:18349029-Follow-Up Studies,
pubmed-meshheading:18349029-Humans,
pubmed-meshheading:18349029-Male,
pubmed-meshheading:18349029-Middle Aged,
pubmed-meshheading:18349029-Neoplasm Metastasis,
pubmed-meshheading:18349029-Organoplatinum Compounds,
pubmed-meshheading:18349029-Switzerland,
pubmed-meshheading:18349029-Time Factors,
pubmed-meshheading:18349029-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.
|
|
pubmed:affiliation |
Institute of Medical Oncology, Inselspital, Bern, Switzerland. markus.borner@insel.ch
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
